Navigation Links
ViroPharma Incorporated Reports Second Quarter 2009 Financial Results
Date:7/29/2009

31, 2008. The six month increase is primarily the result of net sales, offset by our repurchase of $45 million principal amount of our senior convertible notes. Cash flow provided by operating activities for the six months ended June 30, 2009 was $15.9 million.

Looking ahead in 2009

ViroPharma is revising its guidance for the year 2009. The following guidance provided by ViroPharma are projections, based upon numerous assumptions, all of which are subject to certain risks and uncertainties. For a discussion of the risks and uncertainties associated with these forward looking statements, please see the Disclosure Notice below.

For the year 2009, ViroPharma expects the following:

  • Net Cinryze sales are expected to be $80 to $95 million.

  • Research and development (R&D) and selling, general and administrative (SG&A) expenses, including the impact of SFAS 123R, are expected to be $135 to $145 million, which includes approximately $18 million of maribavir-related expenses. SFAS 123R expenses are expected to be between $11 and $13 million.

The company is providing Cinryze net sales guidance and withdrawing Vancocin net sales guidance to align the company's guidance with its growth driver and in light of the August 4, 2009 FDA advisory committee regarding proposed bioequivalence recommendations for Vancocin.

Conference Call and Webcast

ViroPharma is hosting a live teleconference and webcast with senior management to discuss the financial announcement, guidance, and other business results on July 29, 2009 at 9:00 a.m. Eastern Time. To participate in the conference call, please dial (888) 299-4099 (domestic) and (302) 709-8337 (international). After placing the call, please tell the operator you wish
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine news :

1. ViroPharma to Release 2009 Second Quarter Financial Results on July 29, 2009
2. ViroPharma Announces Appointment of Frank Baldino, Jr., Ph.D. to Board of Directors
3. ViroPharma Announces Meeting of FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology on Bioequivalence Recommendations for Oral Vancomycin Hydrochloride Products
4. ViroPharma to Present at Two May Healthcare Conferences
5. ViroPharma to Present at the Cowen & Company 29th Annual Healthcare Conference
6. ViroPharma to Host Investor Teach-In Educational Symposium on Hereditary Angioedema
7. ViroPharma to Release 2008 Fourth Quarter and Full Year Financial Results on February 24, 2009
8. ViroPharma Reports Results of Phase 3 Clinical Trial for Maribavir in Bone Marrow Transplant Patients
9. ViroPharma to Present at the 27th Annual J.P. Morgan Healthcare Conference
10. ViroPharma Provides Update on Vancocin(R)
11. ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Onlinefitnessreview.com recently published a comprehensive review of ... makes this diet work and how it compares to ... components of the program: eliminating foods that may slow ... personal motivation that is needed to succeed; and, learning ... the metabolism rate in top gear. , Nutritionist ...
(Date:5/23/2013)... May 23 (HealthDay News) -- People who eat at ... realize -- and teens are the worst offenders, a ... calories in their meals by as much as 34 ... 23 percent, and adults by as much as 20 ... a news release from the Robert Wood Johnson Foundation, ...
(Date:5/23/2013)... May 23, 2013 Susquehanna Health ... offering a comprehensive babysitting training course for adolescents age ... developed by Indianapolis pediatrician Dr. Patricia Keener after a ... of an adult sitter who didn’t know how to ... development program with a medical basis that aims to ...
(Date:5/23/2013)... "triple negative" carries a poor prognosis, with limited treatment ... cancer cells the way it,s supposed to. New research ... respond to chemotherapy, and identifies a mechanism to rectify ... Li, PhD, and his team at Western,s Schulich School ... Numb functions to promote the death of cancer cells ...
(Date:5/23/2013)... DC (PRWEB) May 23, 2013 The ... a great deal of control over their level of ... weight, yet far fewer are actually taking that control. ... Food Information Council (IFIC) Foundation’s 2013 Food & Health ... respondents say it’s possible to have “a great deal ...
Breaking Medicine News(10 mins):Health News:Onlinefitnessreview.com Publishes 7 Day Belly Blast Diet Review 2Health News:How Many Calories in Your Fast-Food Meal? Guess Again 2Health News:Susquehanna Health Offers Safe Sitter Course for Tweens and Teens 2Health News:Susquehanna Health Offers Safe Sitter Course for Tweens and Teens 3Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 2Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 3Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 4
... beauticians may be affected by phthalates in these products, ... Mothers exposed to a common hairspray chemical while at ... with an abnormally placed urinary opening, a new report ... and nail and hair products contain chemicals called phthalates, ...
... BELLEVUE, Wash., Nov. 26 Edifecs, Inc., ... announced today that CNSI has,selected the Edifecs ... implementation of a new Medicaid Management Information ... Social Services (DSS). The Edifecs Healthcare,Accelerator ...
... research team led by Mitchell Lazar, MD, PhD, ... Metabolism at the University of Pennsylvania School of ... coordinates body rhythms and metabolism. , Lazar ... Penn Veterinary Medicine doctoral student Theresa Alenghat, studied ...
... Micromet, Inc. (Nasdaq: MITI ), a ... of cancer, inflammation and autoimmune diseases, today announced that ... will present at the Piper Jaffray 20th Annual Health ... Wednesday, December 3, 2008. A simultaneous webcast of ...
... help regulate appetite , , WEDNESDAY, Nov. 26 (HealthDay News) -- ... this year, a molecule produced in the small intestine will ... brain the impact of the fat you,ve just consumed. , ... a while. But, researchers are hoping that one day variations ...
... across the world are to share skills and experiences ... Africa, organised by the Wellcome Trust. , The conference ... will take place from 2-5 December at the Africa ... bring together practitioners working in the fields of public ...
Cached Medicine News:Health News:CNSI Selects Edifecs Healthcare Accelerator Suite(TM) for MMIS Solution to Support South Dakota Medicaid Program 2Health News:Molecular partnership controls daily rhythms, body metabolism 2Health News:Micromet to Present at the Piper Jaffray 20th Annual Health Care Conference 2Health News:Micromet to Present at the Piper Jaffray 20th Annual Health Care Conference 3Health News:Micromet to Present at the Piper Jaffray 20th Annual Health Care Conference 4Health News:Fat-Sensing Hormones Might Fight Obesity 2Health News:International workshop aims to boost public engagement work in developing countries 2Health News:International workshop aims to boost public engagement work in developing countries 3
(Date:5/23/2013)... Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today ... Executive Officer of Neurocrine Biosciences, will be presenting at the ... in Boston.   The live presentation takes place ... 8:20 a.m. Pacific Time.  The presentation will be webcast and ... . If you are unable to attend ...
(Date:5/23/2013)... Hearing health affects a man,s lifestyle, and if ... and professionally engaged, he should address any hearing loss he ... Better Hearing Institute (BHI) is delivering to men ... Week , which leads up to and includes Father,s Day. ... through June 16. To help men address ...
(Date:5/23/2013)... 2013  Hadasit Bio-Holdings Ltd. (TASE: HDST, OTC: ... based on intellectual property developed and owned by ... foremost medical research center, today announced that its ... funding from the Israeli Ministry of Industry and ... support product development and advance clinical trials. Cell ...
Breaking Medicine Technology:Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 2Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 3Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 4Hadasit Bio-Holdings Ltd. Portfolio Company - Cell Cure Neurosciences Ltd. Received Additional Government Support 2
... Mich., Aug. 6 Terumo Heart, Inc. announced,that ... Ventricular Assist,System (LVAS) took place on July 30 ... Arbor, Michigan. The surgery was performed by,Francis Pagani, ... Pivotal Trial. DuraHeart is the world,s first third,generation ...
... Nexgen Spine, a leading,developer of innovative spinal implants ... today that it has received CE mark,approval to ... European,Union., "We are delighted that the Physio-L(R) ... Alastair Clemow, Ph.D., President and CEO,of Nexgen Spine. ...
Cached Medicine Technology:First DuraHeart(TM) Left Ventricular Assist System Implanted in the U.S. Pivotal Trial 2Nexgen Spine Receives CE Mark Approval for the Physio-L(R) Artificial Disc 2
... active hormone synthesized within the follicular cells ... synthesized via a series of steps involving: ... (ii) iodination of tyrosine residues in the ... and 3,5-diiodotyrosine (MIT and DIT), and (iii) ...
... factor binding protein-3 (IGFBP-3) is the main binding ... as a component of the ~150 kDa ternary ... of IGF-I or IGF-II and ALS, allowing IGFBP-3, ... the IGFs. The molar concentration of IGFBP-3 in ...
... a monomeric protein produced and stored in ... is released from the pituitary into the ... regulatory control of hypothalamic somatostatin (SS) and ... frequency of GH release appears to be ...
... somatomedin C) is a 7.6 kDa peptide produced ... potent mitogen of cellular proliferation, exerting its actions ... circulation, IGF-I is bound to IGF-binding proteins (IGFBPs), ... by modulating the interaction of IGF-I with the ...
Medicine Products: